Published in Nat Rev Gastroenterol Hepatol on November 22, 2011
Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol (2015) 0.95
Intestinal stricture in Crohn's disease. Intest Res (2015) 0.87
Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol (2015) 0.87
Treatment of peri-anal fistula in Crohn's disease. World J Gastroenterol (2014) 0.87
IBD: Mucosal healing--EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol (2012) 0.77
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology (1976) 15.65
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A (2003) 7.44
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology (2011) 4.88
Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis (2002) 4.13
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol (2007) 4.12
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum (1972) 3.43
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease. Eur Radiol (2007) 2.63
Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut (2009) 2.60
Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol (1996) 2.55
Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology (2008) 2.54
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology (2011) 2.18
Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology (2007) 2.16
Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology (2011) 2.04
Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol (1995) 1.94
Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut (2010) 1.93
Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis (2010) 1.91
Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology (2009) 1.81
Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol (2008) 1.73
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology (2006) 1.60
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol (2003) 1.55
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther (2011) 1.50
Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol (2010) 1.47
Pediatric inflammatory bowel disease and imaging-related radiation: are we increasing the likelihood of malignancy? J Pediatr Gastroenterol Nutr (2011) 1.44
Preoperative MR imaging of anal fistulas: Does it really help the surgeon? Radiology (2001) 1.35
Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn's disease. Acad Radiol (2009) 1.34
MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology (2005) 1.23
Prospective evaluation of MR enterography as the primary imaging modality for pediatric Crohn disease assessment. AJR Am J Roentgenol (2011) 1.20
Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol (2002) 1.17
Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol (2010) 1.17
Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn's disease. Inflamm Bowel Dis (2008) 1.16
Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol (2009) 1.14
Crohn's disease evaluation: comparison of contrast-enhanced MR imaging and single-phase helical CT scanning. J Magn Reson Imaging (2000) 1.12
Early Crohn disease: a proposed definition for use in disease-modification trials. Gut (2010) 1.11
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis (2010) 1.10
Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn's disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis (2010) 1.10
Measuring Crohn's disease activity. Lancet (1980) 1.09
Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study. J Clin Gastroenterol (2011) 1.08
3.0-T MR imaging of the abdomen: comparison with 1.5 T. Radiographics (2008) 1.07
Mural Crohn disease: correlation of dynamic contrast-enhanced MR imaging findings with angiogenesis and inflammation at histologic examination--pilot study. Radiology (2009) 1.02
Crohn disease of the small bowel proximal to the terminal ileum: detection by MR-enteroclysis. Scand J Gastroenterol (2004) 1.00
Magnetic resonance enterography: 4 years experience in a tertiary medical center. Isr Med Assoc J (2011) 0.99
Crohn disease with endoscopic correlation: single-shot fast spin-echo and gadolinium-enhanced fat-suppressed spoiled gradient-echo MR imaging. Radiology (2002) 0.99
Comparison of MR enterography and histopathology in the evaluation of pediatric Crohn disease. Pediatr Radiol (2011) 0.98
Perianal Crohn disease: evaluation of dynamic contrast-enhanced MR imaging as an indicator of disease activity. Radiology (2009) 0.97
Magnetic resonance imaging evaluation of small intestinal Crohn's disease. Best Pract Res Clin Gastroenterol (2006) 0.95
Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin Gastroenterol Hepatol (2005) 0.93
MR enterography of Crohn disease: part 1, rationale, technique, and pitfalls. AJR Am J Roentgenol (2011) 0.91
Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm Bowel Dis (2010) 0.91
Dynamic MRI of the small bowel: usefulness of quantitative contrast-enhancement parameters and time-signal intensity curves for differentiating between active and inactive Crohn's disease. Abdom Imaging (2010) 0.90
MR colonography without bowel purgation for the assessment of inflammatory bowel diseases: diagnostic accuracy and patient acceptance. Inflamm Bowel Dis (2007) 0.89
Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's disease. Inflamm Bowel Dis (2010) 0.89
Role of 3.0-T MR colonography in the evaluation of inflammatory bowel disease. Radiographics (2009) 0.89
Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol (2008) 0.88
Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis (2010) 0.88
Small bowel hydro-MR imaging for optimized ileocecal distension in Crohn's disease: should an additional rectal enema filling be performed? J Magn Reson Imaging (2005) 0.87
Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. AJR Am J Roentgenol (2011) 0.84
Crohn disease of the small bowel: MR enteroclysis versus conventional enteroclysis. Abdom Imaging (2007) 0.83
Magnetic resonance imaging in Crohn's disease. Gastroenterol Clin Biol (2005) 0.83
Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci (2008) 0.83
Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol (2010) 0.82
Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 0.81
Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis (2010) 0.79
Imaging for Crohn disease: use of 3-T MRI in a paediatric setting. J Med Imaging Radiat Oncol (2008) 0.78
Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Aliment Pharmacol Ther (1995) 0.76
Science to practice: can the diagnosis of fibrosis with magnetization contrast MR aid in the evaluation of patients with Crohn disease? Radiology (2011) 0.76
Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature (2007) 7.17
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol (2010) 2.60
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
Tolerogenic dendritic cells: cytokine modulation comes of age. Blood (2006) 2.51
Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol (2006) 2.50
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology (2011) 2.21
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis (2014) 2.17
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.81
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol (2011) 1.65
Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology (2008) 1.62
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol (2007) 1.51
Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study. Dig Dis Sci (2012) 1.50
Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc (2010) 1.49
TNFα inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. Gut (2011) 1.45
Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. J Gastrointest Surg (2013) 1.42
Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol (2005) 1.40
Compliance of the Valsalva graft's pseudosinuses at midterm follow-up with cardiovascular magnetic resonance. Ann Thorac Surg (2011) 1.38
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut (2013) 1.37
The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis (2011) 1.37
MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev (2010) 1.37
The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Gut (2009) 1.36
Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res (2014) 1.36
Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes. Dis Colon Rectum (2009) 1.36
WallFlex colonic stent placement for management of malignant colonic obstruction: a prospective study at two centers. Gastrointest Endosc (2008) 1.33
Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective Western series. Gastrointest Endosc (2010) 1.33
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest (2007) 1.32
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis (2010) 1.32
Stenting of the proximal colon in patients with malignant large bowel obstruction: techniques and outcomes. Gastrointest Endosc (2007) 1.31
The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res (2008) 1.30
Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology (2002) 1.30
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis (2011) 1.29
Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol (2011) 1.29
Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol (2009) 1.27
Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene (2002) 1.22
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology (2004) 1.18
Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol (2008) 1.18
Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol (2003) 1.15
Laparoscopic surgery in rectal cancer: a prospective analysis of patient survival and outcomes. Dis Colon Rectum (2007) 1.14
Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg (2005) 1.13
Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis (2013) 1.12
Risk of postoperative recurrence and postoperative management of Crohn's disease. World J Gastroenterol (2011) 1.12
Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets (2013) 1.11
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev (2013) 1.08
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis (2011) 1.07
Acute small-bowel perforation secondary to capsule endoscopy. Gastrointest Endosc (2007) 1.05
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology (2013) 1.03
Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis (2010) 1.02
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets (2010) 1.01
Microsatellite instability and therapeutic consequences in colorectal cancer. Dig Dis (2012) 1.01
The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol (2009) 1.01
Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J Mol Med (Berl) (2007) 0.99
Metal stents for malignant colorectal obstruction. Minim Invasive Ther Allied Technol (2006) 0.98
Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer (2006) 0.98
Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis (2013) 0.98
Biological therapy for ulcerative colitis: what is after anti-TNF. Curr Drug Targets (2011) 0.97
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett (2010) 0.97
Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One (2008) 0.97
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol (2012) 0.97
High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm. Gastrointest Endosc (2013) 0.97
Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scand J Gastroenterol (2012) 0.96
Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proc Natl Acad Sci U S A (2011) 0.96
Redox equilibrium in mucosal T cells tunes the intestinal TCR signaling threshold. J Immunol (2005) 0.95
Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol (2013) 0.95
Cardiovascular magnetic resonance features of caseous calcification of the mitral annulus. J Cardiovasc Magn Reson (2008) 0.95
Insulated-tip knife endoscopic mucosal resection of large colorectal polyps unsuitable for standard polypectomy. Am J Gastroenterol (2007) 0.95
Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors. Gastroenterology (2013) 0.93
Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion (2008) 0.93
Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? Dig Dis (2012) 0.93
New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut (2013) 0.93
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol (2011) 0.92
Chyluria associated with nephrotic-range proteinuria: pathophysiology, clinical picture and therapeutic options. Nephron Clin Pract (2011) 0.92
Balanced propofol sedation administered by nonanesthesiologists: The first Italian experience. World J Gastroenterol (2011) 0.92